Navigation Links
ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride
Date:8/4/2009

EXTON, Pa., Aug. 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Pharmaceutical Science and Clinical Pharmacology Advisory Committee supports the FDA's Office of Generic Drugs (OGD) draft guidelines on bioequivalence (BE) for Vancocin(R) (vancomycin hydrochloride) capsules. Vancocin is used to treat severe, often life-threatening bacterial infections of the gastrointestinal (GI) tract, Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus. The draft guidelines, if approved, would allow generic manufacturers to use less rigorous standards, including in vitro rather than in vivo testing, for establishing BE rather than using comparative clinical trials. ViroPharma scientists and other leading experts voiced their concern that these new guidelines could jeopardize patient safety.

"We're appreciative that the FDA convened this advisory committee to provide a forum for open debate and discussion regarding a serious public health issue," said Vincent J. Milano, ViroPharma's president and chief executive officer. "While we're disappointed with the vote, we hope that the OGD will take every precaution to ensure that CDI patients will be treated with truly bioequivalent versions of vancomycin, given the life-threatening nature of the disease."

The Advisory Committee was asked if the proposed OGD guidelines and the use of in vitro dissolution methods are sufficient for establishing bioequivalence for generic vancomycin oral capsules. The Advisory Committee voted unanimously in favor of the proposed OGD recommendation to demonstrate bioequivalence through equivalent dissolution in media of pH 1.2, 4.5 and 6.8 for potential vancomycin HCl capsule generic products that:

(a) contain the same active and inactive ingredients in the same amounts as Vancocin( )HCl capsules;

(b) meet currently accepted standards for assay, potency, purity, and stability (equivalent to those in place for Vancocin( )HCl capsules); and

(c) are manufactured according to cGMP.

According to ViroPharma, the proposed in vitro test conditions do not mimic the in vivo environment of the CDI patient and the qualitative and quantitative sameness (Q1Q2) is inadequate given formulation and critical manufacturing process controls and lacks correlation with clinical effects. The company also underscored that the adoption of bioequivalence guidelines is precedent setting and patient safety must be a primary concern.

About Vancocin

Vancocin is the only approved product to treat Clostridium difficile-associated pseudomembranous colitis, one of the most common and devastating hospital-acquired infections. Clostridium difficile infection (CDI) can be severe, and without proper treatment, the associated complications of the disease can be deadly. The incidence of the disease observed in U.S. healthcare facilities more than doubled between 2000 and 2005; between 1999 and 2004, reported mortality rates from C. difficile in the U.S. more than quadrupled to 23.7 per million.

About Clostridium difficile Infection (CDI)

One of the most serious problems facing the U.S. healthcare system today is hospital-acquired infections (HAIs). Clostridium difficile infection is one of the most common and devastating HAIs. The incidence of C. diff observed in U.S. healthcare facilities more than doubled between 2000 and 2005; between 1999 and 2004, reported mortality rates from C. diff in the U.S. more than quadrupled to 23.7 per million. Elderly patients exposed to antibiotics, long-term care patients, or those that have a serious underlying illness, are at greatest risk to contract the disease. Patients with this disease have GI tract conditions that are significantly different from those of a healthy individual due to infection. Typical symptoms include diarrhea, fever, nausea and abdominal pain and dehydration, though cases can lead to life threatening complications such as megacolon, peritonitis and perforation of the colon.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. diff.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Certain statements in this press release may contain forward-looking statements that involve a number of risks and uncertainties. There can be no assurance that the FDA will provide the opportunity for further public discussion, that the FDA will agree with the positions stated in ViroPharma's Vancocin-related submissions or that ViroPharma's efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin through in vitro dissolution testing will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either ViroPharma's citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the FDA's December 2008 bioequivalence guidance for Vancocin, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancocin and our financial performance. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2009 could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
2. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
3. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
4. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
5. ViroPharma to Present at Two May Healthcare Conferences
6. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
7. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
8. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
9. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
10. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. ViroPharma Provides Update on Vancocin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... Aliso Viejo, CA (PRWEB) , ... February 06, 2016 , ... ... can quickly and easily add warm color grades to their footage. A LUT is ... changes every pixel's color to the corresponding color indicated by the table. By manipulating ...
(Date:2/5/2016)... ... , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran the Miami Marathon ... 2003. This year, he ran all 26.2 miles with a green 25-pound ShelterBox strapped ... Heat. , This Sunday, while many are watching the Superbowl, Steven Tonkinson will strap ...
(Date:2/5/2016)... & Salt Lake City, UT (PRWEB) , ... February 05, 2016 ... ... of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi ... New Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association ... restaurants, launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 ... ALS and related diseases that severely limit strength and mobility. , Now ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , February 5, 2016 ... Market Research report states that the global active pharmaceuticals ... and is predicted to reach US$185.9 bn by 2020. ... 6.50% from 2014 to 2020. The title of the ... Captive/Contract Manufactured, by Geography, and by Therapeutic Area) - ...
(Date:2/5/2016)... India , February 5, 2016 ... a new market research report "Fetal (Labor & Delivery) ... & Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, ... published by MarketsandMarkets, This report studies the global market ... market is estimated at USD 6.28 Billion in 2015 ...
(Date:2/5/2016)... February 4, 2016 France , ... , UK, and Israel ). It includes a ... and 3 GD, segmented by age and sex in these markets. GD ... EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis ... , Germany , Italy , ...
Breaking Medicine Technology: